EGFR Monoclonal Antibody (H11) | Invitrogen MA1-12693 product information

product summary

company name :

Invitrogen

other brands :

NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience

product type :

antibody

product name :

EGFR Monoclonal Antibody (H11)

catalog :

MA1-12693

quantity :

100 ug

price :

US 572.00

clonality :

monoclonal

host :

mouse

conjugate :

nonconjugated

clone name :

H11

reactivity :

human, mouse

application :

western blot, ELISA, immunohistochemistry, immunocytochemistry, immunoprecipitation, flow cytometry, immunohistochemistry - paraffin section, blocking or activating experiments

more info or order :

Invitrogen product webpage

citations: 57

Published Application/Species/Sample/Dilution	Reference
immunohistochemistry; human; 1:200; fig 6a western blot; human; loading ...; fig 1b	Engel B, Bowser J, Broaddus R, Carson D. MUC1 stimulates EGFR expression and function in endometrial cancer. Oncotarget. 2016;7:32796-809 pubmed publisher
immunocytochemistry; human; 1:200	Engel B, Constantinou P, Sablatura L, Doty N, Carson D, Farach Carson M, et al. Multilayered, Hyaluronic Acid-Based Hydrogel Formulations Suitable for Automated 3D High Throughput Drug Screening of Cancer-Stromal Cell Cocultures. Adv Healthc Mater. 2015;4:1664-74 pubmed publisher
immunoprecipitation; human immunocytochemistry; human western blot; human	Kyriakakis E, Maslova K, Frachet A, Ferri N, Contini A, Pfaff D, et al. Cross-talk between EGFR and T-cadherin: EGFR activation promotes T-cadherin localization to intercellular contacts. Cell Signal. 2013;25:1044-53 pubmed publisher
immunocytochemistry; human	Gupta A, Mehta R, Alimirah F, Peng X, Murillo G, WIEHLE R, et al. Efficacy and mechanism of action of Proellex, an antiprogestin in aromatase overexpressing and Letrozole resistant T47D breast cancer cells. J Steroid Biochem Mol Biol. 2013;133:30-42 pubmed publisher
blocking or activating experiments; human	Spangler J, Manzari M, Rosalia E, Chen T, Wittrup K. Triepitopic antibody fusions inhibit cetuximab-resistant BRAF and KRAS mutant tumors via EGFR signal repression. J Mol Biol. 2012;422:532-44 pubmed publisher
western blot; human	Collins D, O Donovan N, McGowan P, O SULLIVAN F, Duffy M, Crown J. Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines. Ann Oncol. 2012;23:1788-95 pubmed publisher
western blot; human	Cho J, Pastorino S, Zeng Q, Xu X, Johnson W, Vandenberg S, et al. Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies. Cancer Res. 2011;71:7587-96 pubmed publisher
western blot; human; 1:2000	Hanabata Y, Nakajima Y, Morita K, Kayamori K, Omura K. Coexpression of SGLT1 and EGFR is associated with tumor differentiation in oral squamous cell carcinoma. Odontology. 2012;100:156-63 pubmed publisher
immunoprecipitation; human	DeFazio Eli L, Strommen K, Dao Pick T, Parry G, Goodman L, Winslow J. Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action. Breast Cancer Res. 2011;13:R44 pubmed publisher
immunocytochemistry; human; 2.5 ug/ml	Eifler R, Lind J, Falkenhagen D, Weber V, Fischer M, Zeillinger R. Enrichment of circulating tumor cells from a large blood volume using leukapheresis and elutriation: proof of concept. Cytometry B Clin Cytom. 2011;80:100-11 pubmed publisher
western blot; human; 1:500	Sethi S, Radio N, Kotlarczyk M, Chen C, Wei Y, Jockers R, et al. Determination of the minimal melatonin exposure required to induce osteoblast differentiation from human mesenchymal stem cells and these effects on downstream signaling pathways. J Pineal Res. 2010;49:222-38 pubmed publisher
flow cytometry; human; 1:800 immunocytochemistry; human; 1:500, 1:800 western blot; human	Farabegoli F, Papi A, Orlandi M. (-)-Epigallocatechin-3-gallate down-regulates EGFR, MMP-2, MMP-9 and EMMPRIN and inhibits the invasion of MCF-7 tamoxifen-resistant cells. Biosci Rep. 2011;31:99-108 pubmed publisher
blocking or activating experiments; human; 1,000 ug/ml	Lowe A, Ozer B, Bai Y, Bertics P, Abbott N. Design of surfaces for liquid crystal-based bioanalytical assays. ACS Appl Mater Interfaces. 2010;2:722-31 pubmed publisher
western blot; human	Yamada S, Yanamoto S, Kawasaki G, Mizuno A, Nemoto T. Overexpression of cortactin increases invasion potential in oral squamous cell carcinoma. Pathol Oncol Res. 2010;16:523-31 pubmed publisher
immunohistochemistry; mouse; 1:500	Ozer B, Wiepz G, Bertics P. Activity and cellular localization of an oncogenic glioblastoma multiforme-associated EGF receptor mutant possessing a duplicated kinase domain. Oncogene. 2010;29:855-64 pubmed publisher
western blot; human	Cetin Z, Ozbilim G, Erdogan A, Luleci G, Karauzum S. Evaluation of PTEN and Mcl-1 expressions in NSCLC expressing wild-type or mutated EGFR. Med Oncol. 2010;27:853-60 pubmed publisher
western blot; human	Adam L, Zhong M, Choi W, Qi W, Nicoloso M, Arora A, et al. miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin Cancer Res. 2009;15:5060-72 pubmed publisher
western blot; human	Schicher N, Paulitschke V, Swoboda A, Kunstfeld R, Loewe R, Pilarski P, et al. Erlotinib and bevacizumab have synergistic activity against melanoma. Clin Cancer Res. 2009;15:3495-502 pubmed publisher
western blot; human	Chen Y, Chang C, Hsu H, Chiou S, Lee L, Hseu T. Sennoside B inhibits PDGF receptor signaling and cell proliferation induced by PDGF-BB in human osteosarcoma cells. Life Sci. 2009;84:915-22 pubmed publisher
flow cytometry; human immunohistochemistry; human western blot; human	Al Nedawi K, Meehan B, Kerbel R, Allison A, Rak J. Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR. Proc Natl Acad Sci U S A. 2009;106:3794-9 pubmed publisher
immunoprecipitation; human western blot; human	Corkery B, Crown J, Clynes M, O Donovan N. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. Ann Oncol. 2009;20:862-7 pubmed publisher
western blot; human	Graner M, Alzate O, Dechkovskaia A, Keene J, Sampson J, Mitchell D, et al. Proteomic and immunologic analyses of brain tumor exosomes. FASEB J. 2009;23:1541-57 pubmed publisher
immunoprecipitation; human	Lowe A, Ozer B, Wiepz G, Bertics P, Abbott N. Engineering of PDMS surfaces for use in microsystems for capture and isolation of complex and biomedically important proteins: epidermal growth factor receptor as a model system. Lab Chip. 2008;8:1357-64 pubmed publisher
immunoprecipitation; human western blot; human	Guix M, Faber A, Wang S, Olivares M, Song Y, Qu S, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest. 2008;118:2609-19 pubmed publisher
western blot; human; 1:1000	Wu Y, Li H, Lv X, Wei Q, Li X, Liu X, et al. Overexpression of JKTBP1 induces androgen-independent LNCaP cell proliferation through activation of epidermal growth factor-receptor (EGF-R). Cell Biochem Funct. 2008;26:467-77 pubmed publisher
western blot; human; 1:200-1000	Black P, Brown G, Inamoto T, Shrader M, Arora A, Siefker Radtke A, et al. Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells. Clin Cancer Res. 2008;14:1478-86 pubmed publisher
blocking or activating experiments; human western blot; human	Sakaguchi M, Murata H, Sonegawa H, Sakaguchi Y, Futami J, Kitazoe M, et al. Truncation of annexin A1 is a regulatory lever for linking epidermal growth factor signaling with cytosolic phospholipase A2 in normal and malignant squamous epithelial cells. J Biol Chem. 2007;282:35679-86 pubmed
immunoprecipitation; human western blot; human	Li X, Wei J, Tai H. Activation of extracellular signal-regulated kinase by 12-hydroxyheptadecatrienoic acid in prostate cancer PC3 cells. Arch Biochem Biophys. 2007;467:20-30 pubmed
western blot; mouse	Blair J, Rauh D, Kung C, Yun C, Fan Q, Rode H, et al. Structure-guided development of affinity probes for tyrosine kinases using chemical genetics. Nat Chem Biol. 2007;3:229-38 pubmed
western blot; human; 1:200	Roberg K, Jonsson A, Grenman R, Norberg Spaak L. Radiotherapy response in oral squamous carcinoma cell lines: evaluation of apoptotic proteins as prognostic factors. Head Neck. 2007;29:325-34 pubmed
western blot; human	Qiu Q, Domarkas J, Banerjee R, Katsoulas A, McNamee J, Jean Claude B. Type II combi-molecules: design and binary targeting properties of the novel triazolinium-containing molecules JDD36 and JDE05. Anticancer Drugs. 2007;18:171-7 pubmed
immunocytochemistry; mouse	Choi S, Mendrola J, Lemmon M. EGF-independent activation of cell-surface EGF receptors harboring mutations found in gefitinib-sensitive lung cancer. Oncogene. 2007;26:1567-76 pubmed
western blot; human	Franovic A, Robert I, Smith K, Kurban G, Pause A, Gunaratnam L, et al. Multiple acquired renal carcinoma tumor capabilities abolished upon silencing of ADAM17. Cancer Res. 2006;66:8083-90 pubmed
flow cytometry; human; 1:100 immunocytochemistry; human; 1:20	Chen Z, Mok H, Pflugfelder S, Li D, Barry M. Improved transduction of human corneal epithelial progenitor cells with cell-targeting adenoviral vectors. Exp Eye Res. 2006;83:798-806 pubmed
western blot; human	Fan Q, Knight Z, Goldenberg D, Yu W, Mostov K, Stokoe D, et al. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell. 2006;9:341-9 pubmed
western blot; human	Damiano V, Caputo R, Bianco R, D Armiento F, Leonardi A, De Placido S, et al. Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors. Clin Cancer Res. 2006;12:577-83 pubmed
western blot; human	Márquez D, Chen H, Curran E, Welshons W, Pietras R. Estrogen receptors in membrane lipid rafts and signal transduction in breast cancer. Mol Cell Endocrinol. 2006;246:91-100 pubmed
western blot; human; 1:3000	Kassouf W, Dinney C, Brown G, McConkey D, Diehl A, Bar Eli M, et al. Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells. Cancer Res. 2005;65:10524-35 pubmed
western blot; human; 1:50	Saydam O, Glauser D, Heid I, Turkeri G, Hilbe M, Jacobs A, et al. Herpes simplex virus 1 amplicon vector-mediated siRNA targeting epidermal growth factor receptor inhibits growth of human glioma cells in vivo. Mol Ther. 2005;12:803-12 pubmed
ELISA; human; tbl 2	Traxler P, Allegrini P, Brandt R, Brueggen J, Cozens R, Fabbro D, et al. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res. 2004;64:4931-41 pubmed
ELISA; human; 50 ng/well; tbl 1	Garcia Echeverria C, Pearson M, Marti A, Meyer T, Mestan J, Zimmermann J, et al. In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell. 2004;5:231-9 pubmed
western blot; human; fig 2	Pedersen M, Tkach V, Pedersen N, Berezin V, Poulsen H. Expression of a naturally occurring constitutively active variant of the epidermal growth factor receptor in mouse fibroblasts increases motility. Int J Cancer. 2004;108:643-53 pubmed
	Jacob F, Ming G, Song H. Generation and biobanking of patient-derived glioblastoma organoids and their application in CAR T cell testing. Nat Protoc. 2020;15:4000-4033 pubmed publisher
	Jacob F, Salinas R, Zhang D, Nguyen P, Schnoll J, Wong S, et al. A Patient-Derived Glioblastoma Organoid Model and Biobank Recapitulates Inter- and Intra-tumoral Heterogeneity. Cell. 2020;180:188-204.e22 pubmed publisher
	Dragowska W, Warburton C, Yapp D, Minchinton A, Hu Y, Waterhouse D, et al. HER-2/neu overexpression increases the viable hypoxic cell population within solid tumors without causing changes in tumor vascularization. Mol Cancer Res. 2004;2:606-19 pubmed
	Lammering G, Hewit T, Holmes M, Valerie K, Hawkins W, Lin P, et al. Inhibition of the type III epidermal growth factor receptor variant mutant receptor by dominant-negative EGFR-CD533 enhances malignant glioma cell radiosensitivity. Clin Cancer Res. 2004;10:6732-43 pubmed
	Matheson S, McNamee J, Wang T, Alaoui Jamali M, Tari A, Jean Claude B. The combi-targeting concept: dissection of the binary mechanism of action of the combi-triazene SMA41 in vitro and antitumor activity in vivo. J Pharmacol Exp Ther. 2004;311:1163-70 pubmed
	Cochran J, Kim Y, Olsen M, Bhandari R, Wittrup K. Domain-level antibody epitope mapping through yeast surface display of epidermal growth factor receptor fragments. J Immunol Methods. 2004;287:147-58 pubmed
	Fan Q, Specht K, Zhang C, Goldenberg D, Shokat K, Weiss W. Combinatorial efficacy achieved through two-point blockade within a signaling pathway-a chemical genetic approach. Cancer Res. 2003;63:8930-8 pubmed
	Planque S, Taguchi H, Burr G, Bhatia G, Karle S, Zhou Y, et al. Broadly distributed chemical reactivity of natural antibodies expressed in coordination with specific antigen binding activity. J Biol Chem. 2003;278:20436-43 pubmed
	Gilmour L, MacLeod K, McCaig A, Sewell J, Gullick W, Smyth J, et al. Neuregulin expression, function, and signaling in human ovarian cancer cells. Clin Cancer Res. 2002;8:3933-42 pubmed
	Brahimi F, Matheson S, Dudouit F, McNamee J, Tari A, Jean Claude B. Inhibition of epidermal growth factor receptor-mediated signaling by "Combi-triazene" BJ2000, a new probe for Combi-Targeting postulates. J Pharmacol Exp Ther. 2002;303:238-46 pubmed
	Damstrup L, Wandahl Pedersen M, Bastholm L, Elling F, Skovgaard Poulsen H. Epidermal growth factor receptor mutation type III transfected into a small cell lung cancer cell line is predominantly localized at the cell surface and enhances the malignant phenotype. Int J Cancer. 2002;97:7-14 pubmed
	Lammering G, Lin P, Contessa J, Hampton J, Valerie K, Schmidt Ullrich R. Adenovirus-mediated overexpression of dominant negative epidermal growth factor receptor-CD533 as a gene therapeutic approach radiosensitizes human carcinoma and malignant glioma cells. Int J Radiat Oncol Biol Phys. 2001;51:775-84 pubmed
	Charvat S, Chignol M, Souchier C, Le Griel C, Schmitt D, Serres M. Cell migration and MMP-9 secretion are increased by epidermal growth factor in HaCaT-ras transfected cells. Exp Dermatol. 1998;7:184-90 pubmed
	Bandyopadhyay D, Mandal M, Adam L, Mendelsohn J, Kumar R. Physical interaction between epidermal growth factor receptor and DNA-dependent protein kinase in mammalian cells. J Biol Chem. 1998;273:1568-73 pubmed
	Wikstrand C, Hale L, Batra S, Hill M, Humphrey P, Kurpad S, et al. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res. 1995;55:3140-8 pubmed

product information

Product Type :

Antibody

Product Name :

EGFR Monoclonal Antibody (H11)

Catalog # :

MA1-12693

Quantity :

100 ug

Price :

US 572.00

Clonality :

Monoclonal

Purity :

Protein G

Host :

Mouse

Reactivity :

Human, Mouse

Applications :

Immunocytochemistry: 5 ug/mL, Immunohistochemistry (Paraffin): 2-4 ug/mL, Immunoprecipitation: 2 ug/mg lysate, Western Blot: 0.5-1 ug/mL

Species :

Human, Mouse

Clone :

H11

Isotype :

IgG1, kappa

Storage :

-20 C

Description :

EGFR, epidermal growth factor receptor, is a receptor tyrosine kinases that signals in response to various growth factors. Overexpression has been linked to numerous types of cancer and EGFR is the target of both biological and small molecular therapeutics. EGFR is encoded by the EGFR gene located on chromosome 7 in humans. EGFR belongs to the HER/ERbB family of proteins that includes three other receptor tyrosine kinases, ERbB2, ERbB3, ERbB4. EGFR is a transmembrane receptor and binding of its cognate ligands such as EGF (Epidermal Growth Factor) and TGF alpha (Transforming Growth Factor alpha) to the extracellular domain leads to EGFR dimerization followed by autophosphorylation of the tyrosine residues in the cytoplasmic domain. Overexpression is observed in tumors of the head and neck, brain, bladder, stomach, breast, lung, endometrium, cervix, vulva, ovary, esophagus, stomach and in squamous cell carcinoma.

Immunogen :

HC2 20 d2 cells.

Format :

Liquid

Applications w/Dilutions :

Immunocytochemistry: 5 ug/mL, Immunohistochemistry (Paraffin): 2-4 ug/mL, Immunoprecipitation: 2 ug/mg lysate, Western Blot: 0.5-1 ug/mL

Aliases :

2.7.10.1; 9030024J15Rik; AI552599; avian erythroblastic leukemia viral (v-erbB) oncogene homolog; avian erythroblastic leukemia viral (v-erb-b) oncogene homolog; cell growth inhibiting protein 40; cell proliferation-inducing protein 61; EC 2.7.10.1; egf receptor; Egfr; EGFR-related peptide; epidermal growth factor receptor; epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene homolog, avian); Epidermal growth factor receptor formerly avian erythroblastic leukemia viral (v-erbB) oncogene homolog (Erbb1); epidermal growth factor receptor, formerly avian erythroblastic leukemia viral (v-erbB) oncogene homolog (Erbb1); ERBB; ERBB1; ErbB-1; erb-b2 receptor tyrosine kinase 1; Errb1; Errp; HER1; kinase EGFR; mENA; NISBD2; Oncogene ERBB; PIG61; Proto-oncogene c-ErbB-1; receptor tyrosine-protein kinase erbB-1; Urogastrone; wa2; wa-2; Wa5; waved 2

more info or order :

Invitrogen product webpage